This CME Activity has expired and is no longer available for credit.
Module 3: Considerations in the Management of HIV in Older Adults
Time to Complete
April 20, 2018
April 20, 2019
This is Module 3 in the HealthHIV HIV Primary Care Training and Certificate Program.
0.75 / AMA PRA Category 1 CreditTM
This activity is jointly provided by Postgraduate Institute for Medicine and HealthHIV.
This activity is not supported by educational grants.
In 2014, people aged 50 and older accounted for 45% (428,724) of the estimated 1.1 million people living with HIV infection in the United States. In 2015, people aged 50 and over accounted for 17% of the estimated 39,513 HIV diagnoses in the US.
As more people are infected, diagnosed and begin life-prolonging antiretroviral treatment, the number of people living with and aging with HIV continues to increase. Preventing and managing co-morbid chronic conditions of this aging population is challenging but within the scope of primary care.
Module 3 of HealthHIV’s HIV Primary Care Training and Certificate Program is designed to provide primary care providers and staff a sound overview of best practices regarding the management of HIV and HCV coinfection and HIV and Aging. This activity will present an older man with a history of HIV infection, type 2 diabetes, and other comorbidities who presents with pain in his legs when walking.
As a learner, you will have the opportunity to assess his clinical situation, using the initial chart information provided, and request additional information to determine the key issues in this case. Clinical experts will also weigh in on this scenario for comparison.
This activity has been designed to meet the educational needs of primary care physicians, and other allied healthcare professionals who treat and care for patients with HIV/AIDS.
After completing this activity, the participant will demonstrate the ability to:
Identify common comorbidities in older adults with HIV
Describe the potential impact of long-term antiretroviral therapy on cardiometabolic risk and other comorbidities
Design a strategy to manage both antiretroviral therapy and cardiometabolic risk factors in patients with HIV
Implement evidence-based methods to encourage smoking cessation in patients with HIV
Disclosure of Conflicts of Interest
Postgraduate Institute of Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Jonathan S. Appelbaum, MD, FACP, AAHIVS Laurie L. Dozier Jr., MD Education Director and Professor of Internal Medicine Chair, Department of Clinical Sciences Florida State University College of Medicine Tallahassee, FL
Dr. LeLacheur discloses the following: Consultant: Merck and Viiv
Katherine Brown, MD, FACP, AAHIVS HIV Program Medical Director Group Health Cooperative Seattle, WA
Dr. Brown has no financial relationship to disclose.
Planners and Managers Disclosure
The PIM planners and managers, Trace Hutchinson, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBS, MSN, RN, and Jan Schultz, MSN, RN, CHCP, have nothing to disclose. The HealthHIV planners and managers Dana Cropper-Williams, Brian Hujdich, Sibyl Wilmont, and Michael Shankle, MPH, have nothing to disclose.
AMA PRA Category 1 Credit(s)TM
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and HealthHIV. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medication, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.